InvestBio Portfolio Company Presents Phase I/II Trial Results of Vaccine for Leukemia at American Society of Hematology Annual Meeting
02.29.2008To Date, InvestBio has Raised $20 Million for The Vaccine Company (TVC); TVC Now in Phase III Trials
NEW YORK CITY - February 29, 2008 - Results from a clinical study using technology licensed by The Vaccine Company (TVC), an InvestBio, Inc. portfolio company, were presented at the 49th Annual Meeting of the American Society of Hematology.
The company's PR1 peptide vaccine is derived from two proteins that are either overexpressed or aberrantly expressed in certain cancer cells. Administration of the PR1 vaccine to some patients elicits the proliferation of, PR1-specific cytotoxic T lymphocytes that selectively kill three types of leukemia - myelodysplastic syndrome, acute myelogenous leukemia and chronic myelogenous leukemia.
In the Phase I/II study, the median time in remission for leukemia patients who responded to the PR1 vaccine was three times longer than for non-responders. The Phase I/II clinical trial ran from 2000 to 2006 and was designed to assess the vaccine's safety and ability to elicit an immune response. TVC is now conducting a Pivotal Phase III clinical trial with the vaccine to treat acute myelogenous leukemia.
The PR1 vaccine was developed by Jeffrey Molldrem, M.D., professor at The University of Texas M.D. Anderson Cancer Center. Dr. Molldrem co-founded TVC in 2003, and the company licensed the technology from M.D. Anderson in 2004. M.D. Anderson has an equity interest in TVC.
"Dr. Molldrem's positive results with the PR1 vaccine as reported at ASH gave us confidence to invest in follow-on Phase III and Phase II clinical trials of the vaccine. Early results are validating that confidence," said Gregory Thayer, President & CEO of The Vaccine Company. "We're delighted by the responses that The Vaccine Company was able to present," said Scott Mathis, founder and head of InvestBio and its parent company, Diversified Private Equity Corp. (DPEC Partners). InvestBio creates opportunities for accredited investors to participate in private equity investments in promising biotech companies. InvestBio has raised $20 million for TVC. Mr. Mathis serves on the TVC board of directors.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This press release may contain certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to Algodon Wines & Luxury Development Group (Algodon Partners) and its respective subsidiaries ("the Company") estimated or anticipated future results or other non-historical facts are forward-looking and reflect the Company's current perspective of existing trends and information. These statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date set forth above. The Company undertakes no obligation to update publicly any forward-looking statement, whether because of new information, future events or otherwise.